{"filings":[{"id":2105597,"accession_number":"0001171843-26-005316","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2026-08-06T20:01:21+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q2 net loss $73.5M; barzolvolimab Phase 3 CSU topline data expected Sept/Oct 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $73.5M ($0.94/share) vs $56.6M in Q2 2025; no material revenue.","Cash $717.6M after $323.8M public offering; runway through 2028.","Barzolvolimab Phase 3 CSU enrolled 1,939 patients; topline data Sept/Oct 2026; BLA planned 2027.","Phase 2 prurigo nodularis study failed primary endpoints; discontinued.","CDX-622 Phase 1 showed rapid tryptase reduction; asthma POM study ongoing; expanding into allergic rhinitis and food allergy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1664396,"accession_number":"0001104659-26-083880","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2026-07-15T20:07:43+00:00","items":["5.02","9.01"],"status":"ready","headline":"Celldex Therapeutics CFO Sam Martin to retire by March 31, 2027; search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sam Martin, SVP and CFO, notified of his retirement effective on or about March 31, 2027.","Martin joined Celldex in April 2009 and has served as CFO since July 2017.","Company has initiated a search for a new CFO; Martin will continue until successor or March 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1286716,"accession_number":"0001104659-26-078023","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2026-06-26T12:43:39+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Celldex shareholders OK 3.4M share increase to equity plan; all directors re-elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved 2021 Omnibus Equity Incentive Plan amendment raising share reserve by 3.4M to 12.9M shares.","All nine director nominees elected, including CEO Anthony Marucci and Chair Harry Penner Jr.","Ratification of PwC as independent auditor for FY 2026 passed with 64.7M for vs 174.7K against.","Advisory say-on-pay proposal approved: 59.2M for, 945K against, 479.7K abstain.","Plan amendment also clarifies tax withholding provisions for equity awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98646,"accession_number":"0001171843-26-003153","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex completes Phase 3 CSU enrollment 6 months early; raises $345M; Q1 net loss $78.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 CSU (EMBARQ-CSU1/2) enrolled 1,939 patients, 6 months ahead of guidance; topline data expected Q4 2026, BLA in 2027.","Raised $345M gross in April 2026 public offering; cash at March 31, 2026 was $451.5M, supplemented by ~$323.9M net proceeds.","Q1 2026 net loss $78.7M ($1.18/share) vs $53.8M ($0.81) in Q1 2025; R&D expenses $73M, up from $52.6M.","Phase 1 CDX-622 proof-of-mechanism study in asthma ongoing; Phase 2 PN data summer 2026, AD data late 2026.","Revenue $0 in Q1 2026 (vs $0.7M); management expects cash to fund operations through 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":15000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98645,"accession_number":"0001104659-26-038882","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celldex prices $300M public offering of 10.3M shares at $29.00 for pipeline and barzolvolimab launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 10,345,000 shares at $29.00/share; gross proceeds ~$300M.","Net proceeds expected ~$282M after underwriting discounts and expenses; closing on or about April 6, 2026.","Underwriters granted 30-day option to purchase up to an additional 1,551,750 shares (15%).","Proceeds to fund commercial readiness and launch of barzolvolimab for CSU (if approved), clinical/preclinical development, and bispecific platform.","Lead managers include Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114246,"accession_number":"0001171843-26-001098","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex completes Phase 3 CSU enrollment six months early; cash $518.6M; net loss $1.22/sh Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 CSU program enrolled 1,939 patients across 43 countries; topline data expected Q4 2026, BLA filing planned 2027.","Phase 2 prurigo nodularis and atopic dermatitis studies fully enrolled; data expected summer and late 2026.","Phase 1 CDX-622 (bispecific SCF & TSLP) proof-of-mechanism study in mild-to-moderate asthma initiated.","Q4 2025 net loss $81.3M ($1.22 per share) vs $47.1M ($0.71) year ago; R&D spend rose to $75.3M.","Cash, cash equivalents and marketable securities $518.6M at Dec 31, 2025; runway through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":1545000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130616,"accession_number":"0001171843-25-007179","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q3 net loss $67M; barzolvolimab Phase 2 data positive in urticarias","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $67.0M ($1.01/share) vs $42.1M in Q3 2024; cash use $48.6M in operations.","Cash & securities $583.2M as of Sep 30, 2025; runway through 2027.","Phase 2 barzolvolimab met endpoints in CSU, ColdU, and SD; 71% complete response at 52 weeks (CSU).","Phase 1 CDX-622 (bispecific SCF & TSLP) well tolerated; Part 2 enrollment ongoing.","Teri Lawver hired as SVP, Chief Commercial Officer; Phase 3 ColdU/SD study to start Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":1424000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147163,"accession_number":"0001104659-25-080248","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Celldex Phase 2 barzolvolimab in EoE meets primary endpoint but no clinical benefit; advancement stopped","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: peak mast cell count reduced by -36.0 vs placebo -2.7 (p<0.0001) at Week 12.","No improvement in Dysphagia Symptom Questionnaire (DSQ) (p=0.33) or endoscopic EREFS score (p=0.95).","Company will not advance barzolvolimab in EoE; safety profile favorable at 300 mg Q4W.","Pipeline continues in chronic spontaneous urticaria, atopic dermatitis, prurigo nodularis, and inducible urticaria.","Full study (28-week treatment, 44-week total) outcomes consistent with 12-week results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147162,"accession_number":"0001171843-25-005181","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q2 net loss $56.6M ($0.85/share); cash $630.3M; barzolvolimab shows durable complete response at 76 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $56.6M versus $35.8M in Q2 2024; R&D spend rose to $54.2M on barzolvolimab trials.","Cash and securities $630.3M (down $43M QoQ); company expects runway through 2027.","Phase 2 CSU barzolvolimab: up to 41% complete response at 76 weeks (7 months off-treatment); 48% no quality-of-life impact.","Phase 3 CSU program (EMBARQ-CSU1/2) enrolling globally; Phase 2 CIndU and EoE data due in 2H 2025.","Phase 1 CDX-622 (bispecific SCF/TSLP) in healthy volunteers: Part 1 data expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":1424000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165745,"accession_number":"0001104659-25-057066","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Celldex shareholders approve equity plan increase, elect directors including Denice Torres","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders approved 2M share increase to 2021 Omnibus Plan (total 9.5M shares) with 53.2M for, 963K against.","All 9 director nominees elected, including new director Denice Torres; Karen Shoos' term ended.","Ratification of PricewaterhouseCoopers as auditor for FY2025: 58M for, 119K against.","Advisory say-on-pay approved: 53.5M for, 627K against.","Harry Penner elected Chair of board post-meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165744,"accession_number":"0001171843-25-002980","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q1 net loss widens to $53.8M; Phase 3 CSU enrollment ongoing, multiple data readouts in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $53.8M ($0.81/share) vs $32.8M ($0.56/share) in Q1 2024; R&D expenses rose to $52.6M.","Cash, equivalents and marketable securities $673.3M at March 31, sufficient to fund operations through 2027.","Phase 3 barzolvolimab CSU studies (EMBARQ-CSU1/2) enrolling; Phase 2 EoE enrollment complete; data expected 2025.","76-week CSU Phase 2 data accepted for late-breaking oral presentation at EAACI June 2025.","Bispecific CDX-622 Phase 1 in healthy volunteers enrolling; Part 1 data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":695000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183332,"accession_number":"0001171843-25-001126","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex reports Q4 2024 net loss of $47.1M; cash $725.3M; Phase 3 CSU studies enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and securities $725.3M at Dec 31, 2024; company funded through 2027.","Q4 2024 net loss $47.1M ($0.71/sh) vs $43.3M ($0.83/sh) Q4 2023; R&D expenses $46.9M.","Phase 3 CSU studies EMBARQ-CSU1/2 enrolling ~915 patients each across 40 countries.","Phase 3 CIndU program expected to start in 2025; Phase 2 EoE study fully accrued.","Phase 1 CDX-622 (SCF/TSLP bispecific) initiated; multiple data readouts expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":7020000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199920,"accession_number":"0001171843-24-006056","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q3 net loss $42.1M; barzolvolimab meets Phase 2 CIndU endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $42.1M ($0.64 per share) vs $38.3M in Q3 2023; revenue $3.2M vs $1.5M.","Cash $756.0M as of Sep 30, 2024, down from $802.3M; expects to fund operations through 2027.","Barzolvolimab met all primary/secondary endpoints in Phase 2 CIndU; up to 57.6% complete response in SD.","Global Phase 3 CSU trials (EMBARQ-CSU1/2) actively enrolling; CIndU Phase 3 planned for 2025.","First bispecific CDX-622 (SCF/TSLP) entering Phase 1 in Q4 2024; CDX-585 development halted."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":5845000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215931,"accession_number":"0001171843-24-004603","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q2 net loss $0.54 per share; Phase 3 CSU program launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.8M ($0.54/share) vs $30.5M loss in Q2 2023; revenue $2.5M, up from $0.3M.","Cash $802.3M as of June 30; sufficient to fund operations through 2027.","Initiated global Phase 3 CSU trials (EMBARQ-CSU1/2) in July 2024; actively enrolling.","Phase 2 CIndU study met primary endpoint (negative provocation test) at Week 12; full data 2H 2024.","Barzolvolimab Phase 2 studies ongoing in PN, EoE; AD study to start YE 2024; bispecific CDX-622 enters clinic in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":2654000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235400,"accession_number":"0001104659-24-071512","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Celldex shareholders approve 3.2M share increase to equity plan; director award limits raised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment increasing share reserve from 4.3M to 7.5M shares under 2021 Omnibus Plan.","Non-employee director annual award limit raised to $750K ($1.2M for new directors) effective after stockholder approval.","All eight director nominees elected, including CEO Anthony Marucci and Chair Karen Shoos, with over 54.6M votes for each.","Advisory say-on-pay vote approved with 54.2M for, 0.9M against; auditor ratification passed with 57.8M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235399,"accession_number":"0001171843-24-002570","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex reports Q1 net loss $32.8M; cash $823.8M; Phase 3 CSU studies planned summer 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.8M ($0.56 per share) vs $29.4M ($0.62) in Q1 2023; revenue $0.2M.","Cash, cash equivalents and marketable securities $823.8M, up from $423.6M due to $432.3M net public offering.","Phase 3 CSU studies to initiate summer 2024; 52-week Phase 2 CSU data expected H2 2024.","Phase 2 CIndU enrollment completed (196 patients); 12-week data due H2 2024.","Atopic dermatitis selected as fifth indication; Phase 2 study to start by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":156000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253220,"accession_number":"0001104659-24-029969","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celldex prices upsized $400M common stock offering at $47/share, net proceeds ~$376M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 8,520,000 shares at $47.00 per share; upsized from initial $250M to $400M.","Net proceeds expected ~$376.2M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to an additional 1,278,000 shares.","Proceeds to fund clinical/preclinical development of barzolvolimab, bispecific antibody platform, and pipeline.","Offering expected to close on or about March 5, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253219,"accession_number":"0001171843-24-000966","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q4 2023 net loss $43.3M; cash $423.6M; Phase 3 CSU study planned for summer 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $43.3M ($0.83/share) vs $26.5M ($0.56) in Q4 2022; FY net loss $141.4M ($2.92/share).","Revenue $4.1M in Q4 2023 vs $1.6M in Q4 2022, primarily from Rockefeller University manufacturing agreements.","Cash, cash equivalents and marketable securities $423.6M at Dec 31, 2023 vs $235.3M at Sep 30, 2023; $216.2M raised in Nov 2023 offering.","Barzolvolimab: Positive Phase 2 CSU 12-week data; Phase 3 CSU studies expected to start summer 2024; 52-week data in 2H 2024.","Phase 2 CIndU enrollment nearing completion (data 2H 2024); Phase 2 PN study to start early 2024; cash runway into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":6883000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270681,"accession_number":"0001104659-23-115796","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celldex Therapeutics prices $200.5M public offering of 7.425M shares at $27.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 7,425,000 shares at $27.00 per share; underwriters have 30-day option for 1,113,750 additional shares.","Net proceeds expected ~$188.3M after discounts and expenses.","Proceeds to fund clinical/preclinical development including barzolvolimab and bispecific antibody platform.","Offering expected to close on or about Nov 10, 2023; Jefferies and Leerink Partners lead the underwriting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270680,"accession_number":"0001104659-23-114520","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Celldex announces positive Phase 2 CSU data for barzolvolimab; $12.5M milestone triggered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Barzolvolimab met primary endpoint: LS mean UAS7 change from baseline to week 12 was -23.87 (300mg q8w) vs -10.47 placebo (p<0.0001).","Complete control (UAS7=0) at week 12: 37.5% (300mg q8w), 51.1% (150mg q4w), 22.9% (75mg q4w) vs 6.4% placebo.","Positive Phase 2 data triggers $12.5M milestone payment under settlement agreement with SRS, to be paid in cash.","Phase 1B data in prurigo nodularis showed meaningful itch reduction and clear/almost clear skin with single 3.0 mg/kg dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270679,"accession_number":"0001171843-23-006668","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q3 net loss $38.3M ($0.81/shr); Phase 2 CSU enrollment complete, data by YE 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $38.3M ($0.81 per share) vs $26.8M ($0.57) a year ago; revenue $1.5M.","Cash, equivalents and marketable securities $235.3M, sufficient to fund operations through 2025.","Phase 2 CSU study (n=208) enrollment complete; topline data expected by end of 2023.","Phase 1b prurigo nodularis data accepted for oral presentation at World Congress on Itch (Nov 5-7).","Phase 2 studies in CIndU, EoE ongoing; Phase 2 PN study planned for early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":2752000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287593,"accession_number":"0001171843-23-005101","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q2 net loss $30.5M ($0.65/sh); Phase 2 CSU enrollment complete, topline by YE 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.5M ($0.65/sh) for Q2 2023 vs $36.0M ($0.77/sh) in Q2 2022; cash $252.7M.","Phase 2 CSU enrollment completed with 208 patients, 25% above target; topline data expected by YE 2023.","Phase 1b PN data planned for Q4 2023; Phase 2 EoE initiated, first patient dosed in July.","R&D expenses increased to $26.3M from $20.7M YoY, driven by barzolvolimab costs.","Cash runway sufficient through 2025 to fund planned Phase 2 studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":1234000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307835,"accession_number":"0001104659-23-071597","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Celldex shareholders elect directors, approve 600K share increase, say-on-pay at 1 year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 9 director nominees elected; Dr. Garry A. Neil received highest opposition with 6.2M against.","Ratification of PwC as auditor for FY2023 approved with 43.4M for, 98.6K against.","Amendment to 2021 Omnibus Equity Incentive Plan approved, increasing share reserve by 600K to 4.3M shares.","Advisory say-on-pay passed with 38.7M for; frequency set at 1 year (39.0M voted for 1 year).","Board determined future say-on-pay votes will occur annually until next frequency vote (by 2029)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307834,"accession_number":"0001171843-23-002887","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex reports Q1 2023 net loss $29.4M; advances barzolvolimab Phase 2 studies","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 net loss $29.4M ($0.62/share); revenue $1.0M (vs $0.2M prior year).","Cash, equivalents & securities $278.4M at March 31, 2023; sufficient through 2025.","Phase 2 CSU enrollment completion expected Q3 2023; topline data late 2023/Q1 2024.","Phase 2 EoE study initiation expected June 2023; CDX-585 enters clinic mid-2023.","R&D expenses $26.8M (up from $17.1M) driven by barzolvolimab trials and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":967000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326782,"accession_number":"0001104659-23-035198","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Celldex refutes false report; barzolvolimab PN study continues, Phase 2 subQ planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Inaccurate report at AAD Annual Meeting stated Celldex terminated Phase 1b barzolvolimab study in prurigo nodularis due to SAE.","Celldex clarifies study not terminated; DRC unanimously recommended program proceed despite anaphylactic SAE in complicated patient.","Enrollment closed at 24 patients due to IV administration challenges; blinded study continues with data expected Q4 2023.","Celldex plans Phase 2 subcutaneous study in PN in late 2023 or early 2024.","No safety events reported that would meaningfully impact the barzolvolimab development program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326781,"accession_number":"0001171843-23-001254","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q4 net loss $26.5M ($0.56/sh); barzolvolimab Phase 2 CSU enrollment to complete by Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.5M ($0.56 per share) for Q4 2022; full year net loss $112.3M ($2.40 per share).","Cash, cash equivalents and marketable securities at Dec 31, 2022: $305.0M, down from $323.5M at Sep 30, 2022.","Revenue $1.6M in Q4 2022, $2.4M for full year; R&D expenses $22.9M in Q4, $82.3M for full year.","Barzolvolimab Phase 2 CSU enrollment expected to complete by Q3 2023; topline data late 2023 or Q1 2024.","Rita Jain, M.D. appointed to Board of Directors; Phase 2 EoE study initiation expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":2357000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326780,"accession_number":"0001104659-23-023768","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Celldex appoints Rita Jain, M.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rita Jain, M.D. appointed to Celldex Board effective February 16, 2023.","Dr. Jain receives initial option grant for 17,100 shares vesting over three years.","She previously served as CMO of ChemoCentryx and Immunovant, and SVP/CMO at Akebia.","Dr. Jain currently serves on boards of Provention Bio and AM Pharma supervisory board.","Appointment fills board vacancy; no family relationships or material transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344497,"accession_number":"0001171843-22-007291","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex reports Q3 2022 net loss of $26.8M; cash $323.5M; barzolvolimab data readouts planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share ($0.57) in Q3 2022 vs ($0.45) in Q3 2021; nine-month net loss ($85.8M) includes $15M litigation settlement.","Revenue $0.4M in Q3, down from $0.2M in Q3 2021; R&D expenses rose to $21.6M on barzolvolimab trial and manufacturing.","Cash, cash equivalents and marketable securities $323.5M as of Sept 30, 2022; management says sufficient through 2025.","Phase 2 barzolvolimab studies in CSU, CIndU ongoing; 12-week data from Phase 1b CSU due Feb 2023; CIndU cohort data expected Dec 2022.","CDX-585 (ILT4 & PD-(L)1 bispecific) expected to enter clinic in 2023; CDX-527 (PD-L1 & CD27) discontinued due to evolving competitive landscape and internal hurdles."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":744000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360990,"accession_number":"0001171843-22-005457","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q2 net loss $0.77/sh; barzolvolimab Ph2 studies initiated; settles SRS litigation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $36M ($0.77/sh) vs $13.4M ($0.34/sh) in Q2 2021; revenue $0.2M down from $3.5M.","Cash $356.8M at June 30; management says sufficient through 2025.","Barzolvolimab interim CSU: mean UAS7 reduction 66.6% (1.5mg/kg) and 75.1% (3mg/kg); Phase 2 studies dosed.","Settled Kolltan contingent milestones reduced from $172.5M to $80M; $15M paid in July; $6.3M remeasurement gain.","Deprioritized CDX-1140 program; focusing on barzolvolimab and bispecific platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":337000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360989,"accession_number":"0001104659-22-080483","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2022-07-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Celldex settles Kolltan merger litigation; agrees to up to $80M in milestone payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Celldex pays $15M upfront; future milestones replaced with $12.5M on successful Phase II of CDX-0159 (barzolvolimab) and $52.5M on first regulatory approval.","Litigation in Delaware Court of Chancery to be dismissed with prejudice; each side bears own fees.","Prior milestone obligations under the 2016 Kolltan merger agreement are superseded; remaining payments at Celldex's election in cash or stock.","Settlement releases all claims related to the merger agreement, including those in the lawsuit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380159,"accession_number":"0001104659-22-073889","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Celldex settles Kolltan merger litigation; replaces up to $172.5M milestones with up to $82.5M in payments","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Celldex to pay $15M cash upon signing formal settlement agreement; trial set for June 21, 2022 vacated.","Additional $15M due upon successful completion of Phase 2 trial of CDX-0159 (barzolvolimab), net of $2.5M credit.","Additional $52.5M upon first US FDA or EMA regulatory approval of a surviving company product.","New payments replace prior contingent milestones of up to $172.5M under the 2016 Merger Agreement; broad mutual releases.","Celldex maintains guidance; cash expected to fund operations through 2025 after paying the $15M initial payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380158,"accession_number":"0001104659-22-071880","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Celldex shareholders elect all director nominees, ratify auditor, approve executive compensation at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected; Karen L. Shoos received 39.9M votes for, 1.0M withheld.","Ratification of PricewaterhouseCoopers as auditor for FY2022 approved with 43.3M votes for.","Advisory say-on-pay approved: 40.0M for, 717k against, 180k abstain.","Broker non-votes of 2.5M shares on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380157,"accession_number":"0001171843-22-003323","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q1 net loss $0.49/share; cash $380.5M; barzolvolimab Ph2 starts Q2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.1M ($0.49 per share) vs $16.5M ($0.42) a year ago; revenue fell to $0.2M from $0.7M.","Cash, cash equivalents and marketable securities $380.5M at March 31, 2022; sufficient to fund operations through 2025.","R&D expenses increased to $17.1M from $12.7M; G&A expenses $6.9M vs $4.1M, driven by clinical and commercial planning.","Phase 2 studies of barzolvolimab in chronic spontaneous and inducible urticaria to initiate Q2 2022; Phase 1b CSU data submitted to EAACI.","Barzolvolimab expansion into eosinophilic esophagitis with Phase 2 planned Q4 2022; enrollment continues in prurigo nodularis and inducible urticaria."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":174000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398283,"accession_number":"0001171843-22-001448","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q4 net loss $20.1M; CDX-0159 Phase 2 urticaria studies to start Q2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.1M ($0.43 diluted EPS) for Q4 2021; full year net loss $70.5M ($1.64 EPS).","Cash and marketable securities $408.3M as of Dec 31, 2021; provides runway through 2025.","CDX-0159 Phase 1b CSU data expected July 2022; Phase 2 studies in CSU and CIndU to initiate Q2 2022.","Plans to expand CDX-0159 development into eosinophilic esophagitis (EoE) with Phase 2 trial in Q4 2022.","Subcutaneous formulation of CDX-0159 well tolerated; supports planned Phase 2 doses of 75mg, 150mg, 300mg."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":4651000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398282,"accession_number":"0001104659-22-008977","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2022-01-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Celldex amends bylaws to implement proxy access for shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved proxy access on Jan 25, 2022, adding Article III Section 13 to bylaws.","Stockholders or group owning at least 3% of stock continuously for 3 years may nominate directors.","Maximum nominees is greater of 2 individuals or 20% of board, subject to requirements.","Proxy access will first apply for the 2023 annual meeting of shareholders.","Full amendment text filed as Exhibit 3.1 to this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417309,"accession_number":"0001171843-21-007741","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex reports Q3 net loss of $20.5M, cash $423M, CDX-0159 95% complete response.","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.5M ($0.45/share) in Q3 2021; revenue $0.2M, vs net loss $14.2M ($0.36/share) in Q3 2020.","Cash, cash equivalents & marketable securities $423.1M at Sept 30, 2021, up from $164M at June 30; cash runway through 2025.","CDX-0159 Phase 1b in inducible urticaria: 95% complete response (18/19) after single dose; median response duration 77+ days (cold urticaria) and 57+ days (symptomatic dermographism).","Completed $287.5M gross public offering in July 2021; net proceeds $269.9M.","CDX-1140 combo with pembrolizumab shows confirmed partial response in head and neck cancer; ovarian expansion enrolling for CDX-527."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":4317000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434863,"accession_number":"0001171843-21-005572","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex reports Q2 2021 net loss of $13.4M; raises $287.5M in follow-on offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.4M ($0.34/share) vs $11.0M ($0.50/share) in Q2 2020; revenue $3.5M vs $0.2M.","Cash $164.0M at June 30, 2021; July follow-on offering added $287.5M gross ($270M net), extending runway through 2025.","CDX-0159 Phase 1b: 95% complete response in chronic inducible urticaria; 87% skin mast cell depletion with single dose.","Plan to initiate CDX-0159 study in prurigo nodularis in Q4 2021 and subcutaneous formulation Phase 1 in Q3 2021.","CDX-1140 expansion cohorts recruiting; CDX-527 dose escalation completed, expansion cohorts planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":4165000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434862,"accession_number":"0001104659-21-092099","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2021-07-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celldex prices upsized $250M public offering at $42/share; net proceeds ~$234.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Celldex priced 5,952,381 shares at $42.00 per share in an upsized public offering for $250M gross proceeds.","Expected net proceeds of ~$234.8M after underwriting discounts and estimated expenses.","Proceeds to fund clinical development of CDX-0159 and other pipeline candidates, and bispecific antibody platform.","Underwriters have 30-day option to purchase up to 892,857 additional shares at the same price.","Offering expected to close July 16, 2021; joint book-runners: Jefferies, SVB Leerink, Guggenheim, Cantor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434861,"accession_number":"0001104659-21-091151","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2021-07-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Celldex reports 100% clinical response rate and 95% complete response for CDX-0159 in Phase 1b inducible urticaria","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["19 of 19 patients (100%) showed clinical response; 18 of 19 (95%) achieved complete response by provocation testing.","Rapid onset: complete responses by week 1 (cold urticaria) and week 4 (symptomatic dermographism); median duration 77+ and 57+ days.","Single 3 mg/kg dose suppressed serum tryptase and depleted skin mast cells (87% depletion); well tolerated with mild reversible adverse events.","Subcutaneous formulation enters clinic Q3 2021; Phase 2 urticaria studies start H1 2022; prurigo nodularis study Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434860,"accession_number":"0001104659-21-088220","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2021-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Celldex enters amended employment agreements with 10 executives, new salaries and bonus targets","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Marucci base salary $680,908 (60% bonus); CFO Martin $412,820 (40% bonus).","Initial term through Dec 31, 2021, auto-renew yearly unless 90-day notice.","Severance: 200% base salary lump sum on termination w/o cause or for good reason, plus 18 months COBRA.","25% of unvested equity vests immediately on such termination.","Agreements standardize language; prior agreements restated effective July 1, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}